Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2015 October;106(5 Suppl 1) > Minerva Medica 2015 October;106(5 Suppl 1):9-11





A Journal on Internal Medicine

Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,236




Minerva Medica 2015 October;106(5 Suppl 1):9-11

language: English

Asymmetric dimethylarginine (ADMA): will be or will not be a new revolutionary biomarker of bronchial asthma?

Calabrese C. 1, Carpagnano G. E. 2, Patella V. 3, Vatrella A. 4, Santus P. 5

1 Department of Cardio-Thoracic and Respiratory Sciences, Second University of Naples, Naples, Italy;
2 Section of Respiratory Medicine, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy;
3 Division of Allergy and Clinical Immunology, Battipaglia Hospital, Department of Medicine, ASL Salerno, Salerno, Italy;
4 Department of Medical Sciences, Azienda Ospedaliera S. Giovanni di Dio e Ruggi D’Aragona, Salerno, Italy;
5 Department of Health Sciences, Unit of Pulmonary Rehabilitation, University of Milan, Fondazione Salvatore Maugeri, Scientific Institute of Milan‑IRCCS, Milan, Italy


Carraro et al. measured asymmetric dimethylarginine (ADMA) in the exhaled breath condensate (EBC) obtained from children with asthma and from healthy subjects. The authors demonstrated higher levels of ADMA in EBC of asthmatics compared to controls. ADMA levels in EBC did not correlate with serum levels, lung function parameters, and fractional exhaled nitric oxide. ADMA levels in EBC did not significantly differ between asthmatic patients regularly treated with inhaled steroids and those who were steroid naïve. Further studies are necessary in order to evaluate the role of this biomarker in the characterization of phenotypes of severe bronchial asthma.

top of page

Publication History

Cite this article as

Corresponding author e-mail